233 related articles for article (PubMed ID: 34889354)
1. Managing therapy-associated neurotoxicity in children with ALL.
Bhojwani D; Bansal R; Wayne AS
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):376-383. PubMed ID: 34889354
[TBL] [Abstract][Full Text] [Related]
2. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
[TBL] [Abstract][Full Text] [Related]
3. Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.
Katsin M; Shman T; Migas A; Lutskovich D; Serada Y; Khalankova Y; Kostina Y; Dubovik S
Front Immunol; 2024; 15():1380451. PubMed ID: 38765003
[TBL] [Abstract][Full Text] [Related]
4. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
5. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
Tan AP
Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
[TBL] [Abstract][Full Text] [Related]
6. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
[TBL] [Abstract][Full Text] [Related]
7. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Karschnia P; Jordan JT; Forst DA; Arrillaga-Romany IC; Batchelor TT; Baehring JM; Clement NF; Gonzalez Castro LN; Herlopian A; Maus MV; Schwaiblmair MH; Soumerai JD; Takvorian RW; Hochberg EP; Barnes JA; Abramson JS; Frigault MJ; Dietrich J
Blood; 2019 May; 133(20):2212-2221. PubMed ID: 30808634
[TBL] [Abstract][Full Text] [Related]
8. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
9. Tumor inflammation-associated neurotoxicity.
Mahdi J; Dietrich J; Straathof K; Roddie C; Scott BJ; Davidson TB; Prolo LM; Batchelor TT; Campen CJ; Davis KL; Gust J; Lim M; Majzner RG; Park JR; Partap S; Ramakrishna S; Richards R; Schultz L; Vitanza NA; Wang LD; Mackall CL; Monje M
Nat Med; 2023 Apr; 29(4):803-810. PubMed ID: 37024595
[TBL] [Abstract][Full Text] [Related]
10. Neurotoxicity Biology and Management.
Danish H; Santomasso BD
Cancer J; 2021 Mar-Apr 01; 27(2):126-133. PubMed ID: 33750072
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
12. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy.
Amidi Y; Eckhardt CA; Quadri SA; Malik P; Firme MS; Jones DK; Jain A; Danish HH; Rubin DB; Jacobson CA; Cash SS; Lee JW; Dietrich J; Westover MB
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450377
[TBL] [Abstract][Full Text] [Related]
13. Cytokines in CAR T Cell-Associated Neurotoxicity.
Gust J; Ponce R; Liles WC; Garden GA; Turtle CJ
Front Immunol; 2020; 11():577027. PubMed ID: 33391257
[TBL] [Abstract][Full Text] [Related]
14. Neurological updates: neurological complications of CAR-T therapy.
Tallantyre EC; Evans NA; Parry-Jones J; Morgan MPG; Jones CH; Ingram W
J Neurol; 2021 Apr; 268(4):1544-1554. PubMed ID: 33140239
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know.
Neill L; Rees J; Roddie C
Pract Neurol; 2020 Aug; 20(4):285-293. PubMed ID: 32503897
[TBL] [Abstract][Full Text] [Related]
16. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
[TBL] [Abstract][Full Text] [Related]
17. How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity.
Santomasso BD; Gust J; Perna F
Blood; 2023 May; 141(20):2443-2451. PubMed ID: 36877916
[TBL] [Abstract][Full Text] [Related]
18. Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy.
Tang JP; Peters CW; Quiros C; Wang X; Klomhaus AM; Yamada RE; Timmerman JM; Moore TB; Nowicki TS
Cancer Immunol Res; 2022 Dec; 10(12):1433-1440. PubMed ID: 36259217
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
[TBL] [Abstract][Full Text] [Related]
20. Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series.
Fontanelli L; Pizzanelli C; Milano C; Cassano Cassano R; Galimberti S; Rossini MI; Santo I; Turco F; Bonanni E; Siciliano G; Orciuolo E; Baldacci F
Neurol Sci; 2023 Sep; 44(9):3291-3297. PubMed ID: 37160803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
